IVRO Announces Strong FY '25 First Quarter Sales & Net Income Advances
InVitro International (OTCQB: IVRO) reported strong financial results for Q1 FY '25. The company achieved sales of $244,143, marking a 15.4% increase compared to Q1 FY '24 sales of $211,625. Net income showed significant growth, reaching $33,855, representing a 91.6% increase from the previous year's Q1 figure of $17,667.
CEO W. Richard Ulmer expressed satisfaction with the quarter's progress, highlighting the company's recently announced M&A activity in Europe. Following challenges from Covid and inflation, the company maintains a vision of continued global growth in non-animal test technologies.
InVitro International (OTCQB: IVRO) ha riportato risultati finanziari solidi per il primo trimestre dell'anno fiscale '25. L'azienda ha raggiunto vendite di $244,143, segnando un aumento del 15,4% rispetto alle vendite del primo trimestre dell'anno fiscale '24, pari a $211,625. Il reddito netto ha mostrato una crescita significativa, raggiungendo $33,855, rappresentando un aumento del 91,6% rispetto al dato del primo trimestre dell'anno precedente, che era di $17,667.
Il CEO W. Richard Ulmer ha espresso soddisfazione per i progressi del trimestre, evidenziando l'attività di M&A recentemente annunciata in Europa. Nonostante le sfide derivanti dal Covid e dall'inflazione, l'azienda mantiene una visione di continua crescita globale nelle tecnologie di test non animali.
InVitro International (OTCQB: IVRO) informó sobre sólidos resultados financieros para el primer trimestre del año fiscal '25. La compañía logró ventas de $244,143, marcando un aumento del 15.4% en comparación con las ventas del primer trimestre del año fiscal '24, que fueron de $211,625. El ingreso neto mostró un crecimiento significativo, alcanzando $33,855, lo que representa un aumento del 91.6% respecto a la cifra del primer trimestre del año anterior de $17,667.
El CEO W. Richard Ulmer expresó satisfacción por el progreso del trimestre, destacando la reciente actividad de fusiones y adquisiciones en Europa. Tras los desafíos del Covid y la inflación, la compañía mantiene una visión de crecimiento global continuo en tecnologías de prueba no animal.
InVitro International (OTCQB: IVRO)는 2025 회계연도 첫 분기에 대한 강력한 재무 결과를 보고했습니다. 이 회사는 $244,143의 매출을 달성했으며, 이는 2024 회계연도 첫 분기 매출인 $211,625에 비해 15.4% 증가한 것입니다. 순이익은 크게 증가하여 $33,855에 이르렀으며, 이는 지난해 첫 분기 $17,667에 비해 91.6% 증가한 수치입니다.
CEO W. Richard Ulmer는 분기의 진행 상황에 대한 만족감을 표현하며 최근 유럽에서 발표된 인수합병 활동을 강조했습니다. 코로나19와 인플레이션의 어려움에도 불구하고, 회사는 비동물 테스트 기술의 지속적인 글로벌 성장 비전을 유지하고 있습니다.
InVitro International (OTCQB: IVRO) a annoncé des résultats financiers solides pour le premier trimestre de l'exercice '25. L'entreprise a réalisé des ventes de $244,143, marquant une augmentation de 15,4% par rapport aux ventes du premier trimestre de l'exercice '24 qui étaient de $211,625. Le revenu net a montré une croissance significative, atteignant $33,855, représentant une augmentation de 91,6% par rapport au chiffre du premier trimestre de l'année précédente qui était de $17,667.
Le PDG W. Richard Ulmer a exprimé sa satisfaction quant aux progrès réalisés au cours du trimestre, soulignant les récentes activités de fusions et acquisitions en Europe. Suite aux défis posés par la Covid et l'inflation, l'entreprise maintient une vision de croissance mondiale continue dans les technologies de test sans animaux.
InVitro International (OTCQB: IVRO) berichtete über starke finanzielle Ergebnisse für das erste Quartal des Geschäftsjahres '25. Das Unternehmen erzielte einen Umsatz von $244,143, was im Vergleich zum Umsatz von $211,625 im ersten Quartal des Geschäftsjahres '24 einem Anstieg von 15,4% entspricht. Der Nettogewinn verzeichnete ein signifikantes Wachstum und erreichte $33,855, was einen Anstieg von 91,6% gegenüber dem Nettogewinn von $17,667 im gleichen Zeitraum des Vorjahres darstellt.
CEO W. Richard Ulmer äußerte Zufriedenheit mit dem Fortschritt des Quartals und hob die kürzlich angekündigten M&A-Aktivitäten in Europa hervor. Trotz der Herausforderungen durch Covid und Inflation verfolgt das Unternehmen die Vision eines fortgesetzten globalen Wachstums in der Technologie für nicht-tierische Tests.
- Sales increased 15.4% year-over-year to $244,143
- Net income grew 91.6% to $33,855
- New M&A activity in Europe expanding market presence
- None.
Placentia, California--(Newsfile Corp. - February 4, 2025) - InVitro International (OTCQB: IVRO) today announced a solid
InVitro International's CEO and acting President, W. Richard Ulmer said: "Together with our newly announced M & A activity in Europe, our team is pleased with FY '25 first Quarter progress. Following Covid and inflationary years' challenges, InVitro International's vision of the future is continued global growth for our own, as well as all, NON-Animal test technologies."
About InVitro International, Inc.
InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology-driven provider of non-animal testing methods. The Company's testing technologies are designed to produce data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services
This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.
Company Contact:
W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
invitro@invitrointl.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239499
FAQ
What was IVRO's Q1 FY '25 revenue growth compared to Q1 FY '24?
How much did IVRO's net income grow in Q1 FY '25?
What strategic expansion has IVRO announced in Europe?
How is IVRO performing after COVID and inflationary challenges?
